Early Feasibility Study of the "Easy Light" Fluorecence Imaging System

Sponsor
Professor Fernando Figueira Integral Medicine Institute (Other)
Overall Status
Completed
CT.gov ID
NCT05004623
Collaborator
(none)
5
1
1
2.4
2.1

Study Details

Study Description

Brief Summary

This is an early feasibility study to evaluate the device functionality of an open-field handheld wireless fluorecence imaging system for detection of sentinel lymph nodes in women with cervical and uterine cancers who underwent open surgery.

Condition or Disease Intervention/Treatment Phase
  • Device: Sentinel Lymph Node Biopsy
N/A

Detailed Description

This study was designed to clinically evaluate the functionality of an prototype of our near-infrared fluorescence device named Easy Light. In brief, this device is an open-field handheld wireless fluorecence imaging system that allows real-time visualization of fluorescent dyes such as indocyanine green (ICG) using smartphones and tablets. The handheld is a rechargeable device responsible for excitation of the operative field with infra-red lighting and for capturing the fluorescence emitted by de fluorescent dye to be visualized via wi-fi in the smartphones and tablets using a pre-installed application software. Following the standards of near-infrared fluorescence for detection of sentinel lymph nodes in gynecological malignancies, the hypothesis was the identification of sentinel lymph nodes after lymphatic mapping by interstitial indocyanine green injection in the cervix was feasible with the use of our device named Easy Light.

Study Design

Study Type:
Interventional
Actual Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is an early feasibility study.This is an early feasibility study.
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
Early Feasibility Study of an Open-Field Handheld Wireless Fluorecence Imaging System for Detection of Sentinel Lymph Nodes in Women With Cervical and Uterine Cancers
Actual Study Start Date :
May 26, 2021
Actual Primary Completion Date :
Jul 27, 2021
Actual Study Completion Date :
Aug 6, 2021

Arms and Interventions

Arm Intervention/Treatment
Other: Sentinel Lymph Node Biopsy

Sentinel lymph node biopsy by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device. Lymph node dissection in each hemipelvis should be performed as standard if no sentinel lymph node is detected. Decision of proceeding with complementary lymph node dissection after sentinel lymph node detection is a surgeon decision, according to his/her usual practice.

Device: Sentinel Lymph Node Biopsy
Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.

Outcome Measures

Primary Outcome Measures

  1. The ability to detect sentinel lymph nodes. [Intraoperativelly]

    The ability to detect at least one sentinel lymph node per patient during open surgeries.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Patients with biopsy-proven cervical or uterine cancers;

  2. Clinical stage I or II, according to FIGO - The International Federation of Gynecology and Obstetrics;

  3. Indication for sentinel lymph node biopsy with or without complementary lymphadenectomy by her medical assistant;

  4. Performance status of 0-2;

  5. No synchronous malignancies or previous oncological treatments such as radiation or major abdominal surgery;

  6. Absence of neuro-psychiatric disorders, apparent or confirmed infections, history of drug allergies, limiting obesity for surgery, and pregnancy or breast feeding;

  7. Appropriated cardio-respiratory, hepato-renal and hematological reserves;

  8. Signing of the Consent Form.

Exclusion Criteria:
  1. Perioperative impossibility to inject the fluorescent dye indocyanine green in the cervical region due to any locorregional reason.

Contacts and Locations

Locations

Site City State Country Postal Code
1 IMIP - Instituo de Medicina Integral Professor Fernando Figueira Recife Pernambuco Brazil 50070-550

Sponsors and Collaborators

  • Professor Fernando Figueira Integral Medicine Institute

Investigators

  • Principal Investigator: Thales P Batita, PhD, IMIP, Department of Surgery/Oncology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Thales Paulo Batista, Consulting, Professor Fernando Figueira Integral Medicine Institute
ClinicalTrials.gov Identifier:
NCT05004623
Other Study ID Numbers:
  • 45814621.5.0000.5201
First Posted:
Aug 13, 2021
Last Update Posted:
Aug 13, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Thales Paulo Batista, Consulting, Professor Fernando Figueira Integral Medicine Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 13, 2021